CD34 and acute lymphoblastic leukemia: Indeed, both limited dilution and patient-derived xenograft assays showed that AraC + QC failed to reduce LSC-enriched ALL L-LTC-ICs and hCD45+CD34+ cells (Figs. 3 and 5).